IBDEI1YX ; ; 20-MAY-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;OCT 15, 2014
 Q:'DIFQR(358.4)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.4,374,0)
 ;;=REPAIR-COMPLEX-FACE^23^32
 ;;^UTILITY(U,$J,358.4,375,0)
 ;;=REPAIR-COMPLEX-NK/HAND/FT^24^32
 ;;^UTILITY(U,$J,358.4,376,0)
 ;;=REPAIR-COMPLEX-TRUNK^21^32
 ;;^UTILITY(U,$J,358.4,377,0)
 ;;=TISSUE REARRANGEMENT-FACE/NECK/HAND/FOOT^36^32
 ;;^UTILITY(U,$J,358.4,378,0)
 ;;=TISSUE REARRANGEMENT-SCALP/ARMS/LEGS^35^32
 ;;^UTILITY(U,$J,358.4,379,0)
 ;;=TISSUE REARRANGEMENT-TRUNK^34^32
 ;;^UTILITY(U,$J,358.4,380,0)
 ;;=REPAIR-COMPLEX-SCALP^22^32
 ;;^UTILITY(U,$J,358.4,381,0)
 ;;=TISSUE REARRANGEMENT-EYELID/NOSE/EAR/LIP^37^32
 ;;^UTILITY(U,$J,358.4,382,0)
 ;;=BIOPSY^1^32
 ;;^UTILITY(U,$J,358.4,383,0)
 ;;=TISSUE REARRANGEMENT-ANY AREA^38^32
 ;;^UTILITY(U,$J,358.4,384,0)
 ;;=NEW PATIENT^3^33
 ;;^UTILITY(U,$J,358.4,385,0)
 ;;=ESTABLISHED PATIENT^1^33
 ;;^UTILITY(U,$J,358.4,386,0)
 ;;=CONSULTATIONS^2^33
 ;;^UTILITY(U,$J,358.4,387,0)
 ;;=RISK FACTOR REDUCTION-INDIV^7^34
 ;;^UTILITY(U,$J,358.4,388,0)
 ;;=OTHER^3^34
 ;;^UTILITY(U,$J,358.4,389,0)
 ;;=EDUCATION/TRAINING^1^34
 ;;^UTILITY(U,$J,358.4,390,0)
 ;;=MEDICAL NUTRITION THERAPY^2^34
 ;;^UTILITY(U,$J,358.4,391,0)
 ;;=PREVENTIVE MEDICINE-NEW PT^5^34
 ;;^UTILITY(U,$J,358.4,392,0)
 ;;=PREVENTIVE MEDICINE-EST PT^4^34
 ;;^UTILITY(U,$J,358.4,393,0)
 ;;=RISK FACTOR REDUCTION-GRP^6^34
 ;;^UTILITY(U,$J,358.4,394,0)
 ;;=WOUND TREATMENT^8^34
 ;;^UTILITY(U,$J,358.4,395,0)
 ;;=DIABETES W/O COMPLICATION^1^35
 ;;^UTILITY(U,$J,358.4,396,0)
 ;;=DIABETES W/KETOACIDOSIS^3^35
 ;;^UTILITY(U,$J,358.4,397,0)
 ;;=DIABETES W/HYPEROSMOLARITY^2^35
 ;;^UTILITY(U,$J,358.4,398,0)
 ;;=DIABETES W/OTHER COMA^6^35
 ;;^UTILITY(U,$J,358.4,399,0)
 ;;=DIABETES W/RENAL MANIFESTATIONS^9^35
 ;;^UTILITY(U,$J,358.4,400,0)
 ;;=DIABETES W/NEUR MANIFESTATIONS  ^4^35
 ;;^UTILITY(U,$J,358.4,401,0)
 ;;=DIABETES W/PERIPH. CIRC D/O'S    ^8^35
 ;;^UTILITY(U,$J,358.4,402,0)
 ;;=DIABETES W/OTHER SPECIFIED MANIFEST^7^35
 ;;^UTILITY(U,$J,358.4,403,0)
 ;;=DIABETES W/UNSPEC. COMPLICATION^10^35
 ;;^UTILITY(U,$J,358.4,404,0)
 ;;=ADDITIONAL RENAL MANIFESTATIONS^12^35
 ;;^UTILITY(U,$J,358.4,405,0)
 ;;=NERVE ROOT AND PLEXUS DISORDERS^15^35
 ;;^UTILITY(U,$J,358.4,406,0)
 ;;=ADDITIONAL PERIPHERAL CIRC. MANIFEST.^11^35
 ;;^UTILITY(U,$J,358.4,407,0)
 ;;=ADDITIONAL SPECIFIED MANIFESTIONS^13^35
 ;;^UTILITY(U,$J,358.4,408,0)
 ;;=MISCELLANEOUS^14^35
 ;;^UTILITY(U,$J,358.4,409,0)
 ;;=SECONDARY DIABETES^16^35
 ;;^UTILITY(U,$J,358.4,410,0)
 ;;=DIABETES W/OPHTH MANIFESTATIONS^5^35
 ;;^UTILITY(U,$J,358.4,411,0)
 ;;=ASSOCIATED D/O,SIGNS AND SYMPTOMS^17^35
 ;;^UTILITY(U,$J,358.4,412,0)
 ;;=NEW PATIENT^3^36
 ;;^UTILITY(U,$J,358.4,413,0)
 ;;=ESTABLISHED PATIENT^2^36
 ;;^UTILITY(U,$J,358.4,414,0)
 ;;=CONSULTATIONS^4^36
 ;;^UTILITY(U,$J,358.4,415,0)
 ;;=PROVIDER WEEKLY VISIT^1^36
 ;;^UTILITY(U,$J,358.4,416,0)
 ;;=DIALYSIS ENCOUNTER^1^37
 ;;^UTILITY(U,$J,358.4,417,0)
 ;;=PERITONEAL DIALYSIS ENCOUNTER^2^37
 ;;^UTILITY(U,$J,358.4,418,0)
 ;;=CARDIOLOGY^3^37
 ;;^UTILITY(U,$J,358.4,419,0)
 ;;=COMPLICATIONS/OTHER^4^37
 ;;^UTILITY(U,$J,358.4,420,0)
 ;;=CYSTIC KIDNEY DISEASE^5^37
 ;;^UTILITY(U,$J,358.4,421,0)
 ;;=DIABETES/DIABETIC RENAL DISEASE^6^37
 ;;^UTILITY(U,$J,358.4,422,0)
 ;;=FLUID/ELECTROLYTES DISORDER^7^37
 ;;^UTILITY(U,$J,358.4,423,0)
 ;;=GENERAL SYMPTOMS^8^37
 ;;^UTILITY(U,$J,358.4,424,0)
 ;;=GENITAL/URINARY^9^37
 ;;^UTILITY(U,$J,358.4,425,0)
 ;;=HEMATOLOGY^10^37
 ;;^UTILITY(U,$J,358.4,426,0)
 ;;=HYPERTENSION PRIMARY^11^37
 ;;^UTILITY(U,$J,358.4,427,0)
 ;;=HYPERTENSION SECONDAY^12^37
 ;;^UTILITY(U,$J,358.4,428,0)
 ;;=HYPERTENSIVE HEART/RENAL^13^37
 ;;^UTILITY(U,$J,358.4,429,0)
 ;;=INFECTIOUS DISEASE^14^37
